SAN DIEGO--(BUSINESS WIRE)--Dec. 15, 2015--
ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), a biopharmaceutical company
focused on the development and commercialization of innovative medicines
to address unmet medical needs in central nervous system disorders,
today announced Julian C. Baker has joined its Board of Directors.
“After more than 20 years as a professional investor, Julian has
extensive experience in financing and building companies in the life
sciences industry,” said Leslie L. Iversen, Ph.D., Chairman of ACADIA’s
Board of Directors. “We welcome Julian to our board and look forward to
his insights as we advance NUPLAZID™ through registration for
Parkinson’s disease psychosis and position ACADIA for strong growth.”
Mr. Baker is a Managing Partner at Baker Brothers Investments, which
manages long-term investment funds focused on publicly traded life
sciences companies, for major university endowments and foundations. Mr.
Baker and his brother Felix Baker, Ph.D., founded the firm in 2000. Mr.
Baker’s career as a fund manager began in 1994 when he co-founded a
biotechnology investing partnership with the Tisch family. Mr. Baker
currently serves on the board of directors of Incyte Corporation,
Genomic Health, Inc., and Idera Pharmaceuticals, Inc. Mr. Baker holds an
A.B. Magna Cum Laude from Harvard University.
About ACADIA Pharmaceuticals
ACADIA is a biopharmaceutical company focused on the development and
commercialization of innovative medicines to address unmet medical needs
in central nervous system disorders. ACADIA has a pipeline of product
candidates led by NUPLAZID™ (pimavanserin), for which we have submitted
a New Drug Application (NDA) in Parkinson’s disease psychosis to the FDA
and which has the potential to be the first drug approved in the United
States for this condition. The FDA has classified the NUPLAZID NDA as
having Priority Review status. Pimavanserin is also in Phase II
development for Alzheimer’s disease psychosis and has successfully
completed a Phase II trial in schizophrenia. ACADIA also has
clinical-stage programs for glaucoma and, in collaboration with
Allergan, Inc., for chronic pain. ACADIA maintains a website at www.acadia-pharm.com
to which we regularly post copies of our press releases as well as
additional information and through which interested parties can
subscribe to receive e-mail alerts.
Statements in this press release that are not strictly historical in
nature are forward-looking statements. These statements include but are
not limited to statements related to the potential for NUPLAZID
(pimavanserin) to be the first drug approved in the United States for
Parkinson’s disease psychosis (PDP) and the potential timing of such
approval, if approved at all, by the FDA; the benefits to ACADIA of Mr.
Baker joining its Board of Directors; the progress, timing and results
of ACADIA’s drug discovery and development programs, either alone or
with a partner, including the progress and expected timing of clinical
trials; and the benefits to be derived from ACADIA’s product candidates,
including pimavanserin. These statements are only predictions based on
current information and expectations and involve a number of risks and
uncertainties. Actual events or results may differ materially from those
projected in any of such statements due to various factors, including
the risks and uncertainties inherent in drug discovery, development,
approval and commercialization, and collaborations with others, and the
fact that past results of clinical trials and past regulatory decisions
may not be indicative of future trial results or future regulatory
decisions, respectively. For a discussion of these and other factors,
please refer to ACADIA’s annual report on Form 10-K for the year ended
December 31, 2014 as well as ACADIA’s subsequent filings with the
Securities and Exchange Commission. You are cautioned not to place undue
reliance on these forward-looking statements, which speak only as of the
date hereof. This caution is made under the safe harbor provisions of
the Private Securities Litigation Reform Act of 1995. All
forward-looking statements are qualified in their entirety by this
cautionary statement and ACADIA undertakes no obligation to revise or
update this press release to reflect events or circumstances after the
date hereof, except as required by law.
View source version on businesswire.com: http://www.businesswire.com/news/home/20151215005412/en/
Source: ACADIA Pharmaceuticals Inc.
ACADIA Pharmaceuticals Inc.
Lisa Barthelemy, Director of